论文部分内容阅读
对哌拉西林和阿米卡星联用以头孢他啶为对照治疗４３例重度院内铜绿假单胞菌肺炎的疗效、细菌清除、不良反应等方面进行了评价，结果表明：两药联用组（２１例）总有效率为７１．４％，细菌清除率为８２．４％，不良反应发生率为９．５％；与头孢他啶组（２２例）比较无显著性差异（Ｐ＞０．０５）。结果揭示：对肝、肾功能正常重度院内铜绿假单胞菌肺炎患者，哌拉西林和阿米卡星联用可作为临床重要治疗方案之一予以选用。
The efficacy of piperacillin and amikacin in treating 43 cases of severe hospital Pseudomonas aeruginosa pneumonia with ceftazidime as control was evaluated in terms of bacterial clearance and adverse reactions. The results showed that the two drugs combined group (21 The total effective rate was 71.4%, the bacterial clearance rate was 82.4% and the adverse reaction rate was 9.5%. There was no significant difference between the two groups (P> 0.05). The results revealed: For liver and renal dysfunction in patients with severe hospital Pseudomonas aeruginosa pneumonia, piperacillin and amikacin combination can be used as one of the clinically important treatment options to be selected.